


## Data Sheet

<b>Product Name:</b>	Amitifadine (hydrochloride)
<b>Cat. No.:</b>	CS-4638
<b>CAS No.:</b>	410074-74-7
<b>Molecular Formula:</b>	C <sub>11</sub> H <sub>12</sub> Cl <sub>3</sub> N
<b>Molecular Weight:</b>	264.58
<b>Target:</b>	Dopamine Transporter; Serotonin Transporter
<b>Pathway:</b>	Neuronal Signaling
<b>Solubility:</b>	DMSO : ≥ 100 mg/mL (377.96 mM); H <sub>2</sub> O : 50 mg/mL (188.98 mM; Need ultrasonic)



H-Cl

### BIOLOGICAL ACTIVITY:

Amitifadine hydrochloride is a serotonin-norepinephrine-dopamine reuptake inhibitor (**SNDRI**), with **IC<sub>50</sub>s** of 12, 23, 96 nM for serotonin, norepinephrine and dopamine in HEK 293 cells, respectively. **IC<sub>50</sub> & Target:** IC<sub>50</sub>: 12 nM (serotonin), 23 nM (norepinephrine), 96 nM (dopamine)<sup>[1]</sup>. **In Vitro:** Amitifadine (DOV 21,947) is an antidepressant drug. **K<sub>i</sub>** values for SERT, NET, and DAT are 99 nM, 262 nM, and 213 nM. The **IC<sub>50</sub>** values for serotonin, norepinephrine and dopamine uptake are 12, 23 and 96 nM, respectively<sup>[1]</sup>. **In Vivo:** The 30 mg/kg Amitifadine dose significantly reduces nicotine self-administration. The 5 and 10 mg/kg doses reduce nicotine self-administration during the first 15 min. of the session when the greatest amount of nicotine is self-administered. The 30 mg/kg Amitifadine dose, but not the lower doses cause a significant reduction in locomotor activity averaged over the 1-hour session and reduce food motivated responding. The 10 mg/kg dose causes hypoactivity at the beginning of the session, but 5 mg/kg does not cause any hypoactivity. The effect of chronic Amitifadine treatment (10 mg/kg) over the course of 15 sessions is also determined. Amitifadine causes a significant reduction in nicotine self-administration, which is not seen to diminish over two consecutive weeks of treatment and a week after enforced abstinence. Amitifadine significantly reduces nicotine self-administration. This prompts further research to determine if Amitifadine might be an effective treatment for smoking cessation<sup>[2]</sup>.

### PROTOCOL (Extracted from published papers and Only for reference)

Animal administration [2] Male Wistar rats (250 g) and Male C57/Bl mice (25 g) were placed in transparent, cylindrical 10-l glass beakers (height 40 cm, internal diameter 19 cm) containing water (24-25°C) to a level of 22 cm. Amitifadine (dissolved in deionized water) was administered orally via feeding tube. Amitifadine were administered to rats and mice in volumes of 1 and 10 mg/kg, respectively.

### References:

[1]. Skolnick P1, et al. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. *Eur J Pharmacol.* 2003 Feb 14;461(2-3):99-104.

[2]. Levin ED, et al. Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats. *Eur J Pharmacol.* 2015 Jun 20;764:30-37.

### CAIndexNames:

3-Azabicyclo[3.1.0]hexane, 1-(3,4-dichlorophenyl)-, hydrochloride (1:1), (1R,5S)-

**SMILES:**

C1C(C=C1)[C@]2(CNC3)[C@@H]3C2=C(C=C1)Cl.[H]Cl

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: [sales@ChemScene.com](mailto:sales@ChemScene.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA